Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Movantik Generic Name & Formulations
Legal Class
Rx
General Description
Naloxegol 12.5mg, 25mg; tabs.
Pharmacological Class
Opioid antagonist (peripheral).
How Supplied
Tabs—30, 90
Manufacturer
Generic Availability
NO
Movantik Indications
Indications
Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation.
Movantik Dosage and Administration
Adult
Discontinue all laxative therapy prior to initiation; may use as needed if suboptimal response after 3 days. Discontinue if opioid pain therapy is also discontinued. Swallow whole. Take on an empty stomach. 25mg once daily in the AM; may reduce to 12.5mg once daily if unable to tolerate. If unable to swallow tab whole: may crush and mix with 4oz of water and drink immediately; refill glass with additional 4oz of water, stir and drink. Also, may give via NG tube (see full labeling). Moderate, severe, or end-stage renal impairment (CrCl <60mL/min): 12.5mg once daily; may increase to 25mg once daily if well tolerated and symptoms continue. Concomitant moderate CYP3A4 inhibitors: if unavoidable, reduce naloxegol to 12.5mg once daily; monitor.
Children
Not established.
Movantik Contraindications
Contraindications
Known or suspected GI obstruction. Patients at increased risk of recurrent obstruction. Concomitant strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole).
Movantik Boxed Warnings
Not Applicable
Movantik Warnings/Precautions
Warnings/Precautions
Risk of GI perforation in those with conditions which might result in impaired integrity of the GI tract wall (eg, Crohn's disease, GI obstruction). Monitor for abdominal pain and/or diarrhea; discontinue if severe symptoms occur (consider restarting at 12.5mg once daily, if appropriate). Monitor for symptoms of opioid withdrawal (esp. patients receiving methadone or having disruptions to the blood brain barrier). Severe hepatic impairment (Child-Pugh Class C): avoid. Pregnancy. Nursing mothers: not recommended.
Movantik Pharmacokinetics
See Literature
Movantik Interactions
Interactions
See Contraindications. Avoid concomitant moderate CYP3A4 inhibitors (eg, diltiazem, erythromycin, verapamil): if unavoidable, reduce dose (see Adults). Avoid concomitant other opioid antagonists, grapefruit, or grapefruit juice. Concomitant strong CYP3A4 inducers (eg, rifampin, carbamazepine, St. John’s Wort): not recommended.
Movantik Adverse Reactions
Adverse Reactions
Abdominal pain, diarrhea, nausea, flatulence, vomiting, headache, hyperhidrosis.
Movantik Clinical Trials
See Literature
Movantik Note
Not Applicable
Movantik Patient Counseling
See Literature
Images
